Background
Overactive bladder (OAB) affects up to 1 in 6 adult men and women in the United States [
1]. The syndrome is characterized by urinary urgency, with or without urgency incontinence, usually with frequency and nocturia, in the absence of infection or other identifiable causes [
2]. Given the symptom bother and impact on quality of life, it is anticipated that many OAB patients would have psychosocial difficulties. A recent review suggested that depression might be associated with OAB [
3]. However most of the published studies were population-based epidemiological surveys. Surprisingly there was been very few papers that focused on OAB patients who presented to clinics [
4‐
8].
Chiara et al. [
6] compared the depression scores between female patients with stress incontinence, urgency incontinence, and mixed incontinence, and showed no differences in the depression scores between the three groups. In contrast, Stach-Lempinen et al. [
7] showed that the odds of depression was significantly higher in female patients with urgency incontinence compared to those with stress incontinence (OR 3.7, 95 % CI 1.30-10.49,
p = 0.026). Melville et al. [
4] also showed that the odds of depression was higher in female patients with urgency incontinence or mixed incontinence compared to stress incontinence (OR 9.2-11.5). None of the studies above recruited a control group. In the only paper that recruited a control group, Zorn et al. [
8] showed that patients with idiopathic urgency incontinence reported higher depression scores than controls who did not have incontinence. Overall the results of the studies were inconclusive.
A few studies have compared urinary incontinence (UI) patients with depression versus UI patients without depression. Melville et al. [
4] showed that there was no difference in the daily UI episodes or the percent with moderate/large UI between UI patients with depression versus those without depression. Sung et al. [
5] studied female obese UI patients, and also showed that there was no difference in the numbers of urgency incontinence episodes between obese UI patients with depression versus obese UI patients without depression. However, two other studies have reported higher Urogenital Distress Inventory (UDI) scores among UI patients with depression [
4,
5].
It is evident that the few publications that have studied the clinical UI population yielded conflicting results [
4‐
8]. All of the studies have recruited patients with a myriad of UI symptoms (stress, urgency, and mixed incontinence) or causes (idiopathic, obstructive, and neurogenic incontinence), thus the relationship between depression and OAB may be confounded. Most studies have examined urinary incontinence (UI) in general but have not focused on OAB specifically. To our knowledge none of the studies have specifically recruited OAB patients, compared OAB patients with versus without depression, and have correlated the severity of their depression and OAB symptoms.
Here we address the gap in the literature by specifically investigating the relationship between depression and OAB in the clinical OAB population. We have: (1) recruited OAB patients and age-matched controls, (2) compared their depression symptoms, (3) compared OAB patients with versus without depression, and (4) performed correlation analyses between the severity of their depression and OAB/incontinence symptoms.
Discussion
The present study specifically recruited OAB patients. We compared the depression symptoms between OAB and controls, and the urinary symptoms between the two OAB subgroups – with and without depression. The results showed that: (1) OAB patients have higher depression scores than controls; (2) OAB patients with depression reported more severe incontinence, greater bother and more impact on quality of life than OAB patients without depression; (3) there are positive correlations between the severity of depression symptoms and OAB/incontinence symptoms among the OAB patients.
27.5 % of OAB patients in our study have depression symptoms based on the HADS-D scale (HADS-D ≥8). Moreover, more than 10 % of OAB patients in our study have moderate to severe depression (HADS-D ≥11). The high prevalence of depression in the clinical OAB population has therapeutic implications. Behaviors associated with depression may impede response to clinical intervention. For example, behavioral therapies for OAB (e.g., bladder training, dietary and fluid modification, pelvic floor muscle exercises) require active participation of the patient. Depressed patients may lack the self-motivation, desire, and persistent effort necessary to have a successful outcome with behavioral therapies. Depression may also influence compliance to pharmacological therapies. Since the goals of OAB treatment are not only to improve symptoms but also to improve quality of life and function, not recognizing depression and its impact may contribute to suboptimal improvement in patient’s global impression of improvement (PGI-I). Urologists or urogynecologists are usually not trained to diagnose and treat clinical depression. However, they can screen OAB patients, particularly those with severe urinary incontinence, for depressive symptoms using the HADS-D scale. HADS-D takes less than a minute for patients to complete. OAB patients that are flagged for depressive symptoms might be considered for referral. It is important to recognize psychosocial comorbidities in patients seeking care because of their potential influence on therapeutics and high prevalence (~30 % of OAB patients have depression, and >10 % have moderate to severe depression).
We have demonstrated the positive associations between the severity of depression symptoms and OAB/incontinence symptoms in this cross-sectional study. However, to the best of our knowledge, the nature behind this association is unknown. It is unclear which came first, the “chicken” or the “egg.” While it is not hard to imagine that the symptoms and functional impairment associated with OAB/incontinence may lead to depression, the possibility that OAB and depression may share a common pathophysiological pathway in some patients deserves further research. Selective serotonin uptake inhibitors are commonly used to manage depression. Reduction of serotonin levels in the central nervous system is associated with increased urinary frequency and bladder contractions, while activation of the central serotonergic system with a 5-HT uptake inhibitor depresses bladder contractions and increases the micturition threshold volume in animal studies [
16]. Thus depression may be mechanistically linked to OAB via the serotonergic pathway. In an earlier clinical study, duloxetine – a serotonin noradrenergic uptake inhibitor – has been shown to improve both the “wet” and “dry” symptoms in OAB patients [
17].
A few population-based cohort studies have tried to clarify the relationship between depression and OAB. In an one-year longitudinal study of women aged 40 years and over, incident cases of depression was predicted by the presence of urgency incontinence at baseline; while incident cases of urgency incontinence was not predicted by depression at baseline [
18]. In two longitudinal studies involving older patients aged 65 and above, depression at baseline predicted new onset urgency incontinence at the 1-year follow up in one study and at the 6-year follow up in the second study [
19,
20]. Studies in the clinical OAB population showed that depression improved with successful treatment of OAB with anticholinergic medications, botulinum toxin A, and InterStim neuromodulation [
21‐
23]. Collectively these studies suggested a causality relationship between depression and OAB/incontinence. Future studies are needed to further examine the mechanistic links between depression and OAB.
It is interesting to note that in Table
2, we demonstrated differences in ICIQ-UI, UDI-6 and IIQ-7 but not in ICIQ-OAB or OAB-q between OAB patients with and without depression. As shown in Table
3, the main difference between OAB patients with and without depression was due to their incontinence rather than their urgency or frequency symptoms. Thus questionnaires that focus more on the incontinence symptoms (ICIQ-UI, UDI-6 or IIQ-7) captured the differences while questionnaires that focus more on urgency/frequency symptoms (OAB-q or ICIQ-OAB) may not have captured a difference.
The current study has limitations: 1) It was a single-institution study with small sample size, thus it may not have sufficient power for more detailed analyses (e.g., adjusting for additional potential covariates such as medical comorbidities in the multivariate analysis); 2) findings from patients seeking care at a tertiary medical center because of the severity of their symptoms may not be generalizable to the general OAB population; and 3) assessment of depression was based on self-reported symptoms. Although the HADS-D is commonly used to screen for depression in the outpatient setting, it is not a diagnostic tool for clinical depression, and it cannot be ascertained without psychiatric evaluation which was not performed here. Despite these limitations, many of the comparisons clearly demonstrated differences. Large multi-institutional studies of the clinical OAB population are needed to further examine these relationships.
Acknowledgements
We would like to thank all the subjects who participated in the study, Vivien Gardner for recruiting the subjects and performance of the study, Aleksandra Klim for IRB and study support, and Alethea Paradis for data management.